{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:30:54Z","timestamp":1786681854693,"version":"build-2736575974"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To systematically review the efficacy of chemotherapy combined with targeted therapy in the handling of advanced triple-negative breast cancer (TNBC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A thorough literature search was carried out across several databases, including PubMed, EMBASE, ScienceDirect, and Chinese medical databases, for case-control trials on TNBC patients treated with chemotherapy combined with targeted therapy versus chemotherapy alone. Two separate researchers extracted the data, and the risk of bias was assessed using the Cochrane Manual 5.3. The meta-analysis was performed using RevMan 5.3. This review followed PRISMA 2020 and was registered in INPLASY (registration ID INPLASY202590085).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following PRISMA guidelines, 2,136 records were identified, and five controlled studies involving 523 participants were included. Meta-analysis of progression-free survival (PFS) suggested a potential improvement in the targeted therapy plus chemotherapy group; however, the pooled result did not reach statistical significance (HR\u00a0=\u00a00.45, 95% CI 0.16\u20131.26; P\u00a0=\u00a00.13). Overall survival (OS) data were insufficient for quantitative meta-analysis, and the available controlled studies did not demonstrate a definitive survival benefit. The objective response rate (ORR) and disease control rate (DCR) were significantly higher with targeted therapy plus chemotherapy than with chemotherapy alone (P &amp;lt; 0.05). No significant increase in adverse events was observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Targeted therapy plus chemotherapy improves tumor response outcomes in patients with advanced or metastatic TNBC without a clear increase in severe adverse events. However, evidence regarding PFS and OS benefits remains inconclusive because of limited studies, heterogeneity, and insufficient survival data.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1903922","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:23:00Z","timestamp":1786681380000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeted therapy plus chemotherapy for advanced or metastatic triple-negative breast cancer: a PRISMA 2020 systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Yanbing","family":"Li","sequence":"first","affiliation":[{"name":"Department II of Oncology, Jiujiang City Key Laboratory of Cell Therapy, JiuJiang NO.1 People's Hospital","place":["Jiujiang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Li","sequence":"additional","affiliation":[{"name":"Department II of Oncology, Jiujiang City Key Laboratory of Cell Therapy, JiuJiang NO.1 People's Hospital","place":["Jiujiang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Shi","sequence":"additional","affiliation":[{"name":"Department II of Oncology, Jiujiang City Key Laboratory of Cell Therapy, JiuJiang NO.1 People's Hospital","place":["Jiujiang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Zuo","sequence":"additional","affiliation":[{"name":"Department II of Oncology, Jiujiang City Key Laboratory of Cell Therapy, JiuJiang NO.1 People's Hospital","place":["Jiujiang, Jiangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/ppo.0000000000000500","article-title":"Epidemiology of triple-negative breast cancer: a review","volume":"27","author":"Howard","year":"2021","journal-title":"Cancer J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071674","article-title":"Advances in systemic therapies for triple negative breast cancer","volume":"381","author":"Leon-Ferre","year":"2023","journal-title":"BMJ"},{"key":"B4","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","article-title":"Recent advances in targeted strategies for triple-negative breast cancer","volume":"16","author":"Zhu","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cmet.2020.10.012","article-title":"Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets","volume":"33","author":"Gong","year":"2021","journal-title":"Cell Metab"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32531-9","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes","year":"2020","journal-title":"Lancet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(18)30285-5","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy272.294","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton","year":"2018","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-820","article-title":"Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer","volume":"14","author":"Hu","year":"2014","journal-title":"BMC Cancer"},{"key":"B13","article-title":"Apatinib suppresses breast cancer cells proliferation and invasion via angiomotin inhibition","volume":"11","author":"Zhang","year":"2019","journal-title":"Am J Transl Res"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.31222\/osf.io\/v7gm2_v1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.31222\/osf.io\/gwdhk_v1","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B16","doi-asserted-by":"crossref","DOI":"10.1002\/9781119536604","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2019"},{"key":"B17","article-title":"Risk of bias in randomized trials and evidence synthesis","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.39489.470347.ad","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.01.065","article-title":"A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis","volume":"32","author":"Brufsky","year":"2021","journal-title":"Ann Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.11569\/wcjd.v24.i5.759","article-title":"Clinical efficacy of low-dose apatinib combined with capecitabine in the treatment of advanced triple-negative breast cancer and its influence on the levels of midkine and platelet factor 4","volume":"36","author":"Song","year":"2023","journal-title":"J Basic Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1093\/annonc\/mdy428.015","article-title":"Effect of apatinib combined with capecitabine on clinical efficacy, progression-free survival and adverse reactions in patients with advanced metastatic triple-negative breast cancer","volume":"19","author":"Wang","year":"2021","journal-title":"Oncol Prog"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy428.015","article-title":"Clinical observation of apatinib combined with capecitabine in the third-line treatment of advanced triple-negative breast cancer","volume":"25","author":"Wang","year":"2020","journal-title":"Chin J Clin Pharmacol Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"670","DOI":"10.14009\/j.issn.1672-2124.2019.06.008","article-title":"Efficacy of apatinib combined with capecitabine in treatment of patients with advanced triple-negative breast cancer","volume":"19","author":"Meng","year":"2019","journal-title":"Eval Anal Drug-Use Hospitals China"},{"key":"B28","doi-asserted-by":"publisher","first-page":"72","DOI":"10.2174\/0115665232283880240301035621","article-title":"Efficacy and safety of pembrolizumab monotherapy or combined therapy in patients with metastatic triple-negative breast cancer: a systematic review and meta-analysis of randomized controlled trials","volume":"25","author":"Araghi","year":"2025","journal-title":"Curr Gene Ther"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1186\/s12885-024-13105-9","article-title":"PD-1\/PD-L1 immune checkpoint inhibitors in the treatment of unresectable locally advanced or metastatic triple negative breast cancer: a meta-analysis on their efficacy and safety","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12041588","article-title":"Efficacy of PARP inhibitor, platinum, and immunotherapy in BRCA-mutated HER2-negative breast cancer patients: a systematic review and network meta-analysis","volume":"12","author":"Sun","year":"2023","journal-title":"J Clin Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2022.2125381","article-title":"Efficacy and safety of neoadjuvant therapy for triple-negative breast cancer: a Bayesian network meta-analysis","volume":"22","author":"Yu","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.019","article-title":"ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer","volume":"32","author":"Gennari","year":"2021","journal-title":"Ann Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1903922\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T04:23:03Z","timestamp":1786681383000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1903922\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":33,"alternative-id":["10.3389\/fonc.2026.1903922"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1903922","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"article-number":"1903922"}}